Trial Profile

A Phase 2b clinical trial of Entacingene-turiparvovec (AAV-CNGB3) for the Treatment of Achromatopsia (ACHM)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entacingene turiparvovec (Primary)
Indications Colour vision defects
Focus Adverse reactions

Most Recent Events

11 Aug 2022 According to MeiraGTx media release, this trial will use material manufactured at MeiraGTx's cGMP facility in London, United Kingdom.
15 Mar 2022 New trial record
10 Mar 2022 According to MeiraGTx media release, expects to initiate this later stage clinical study in 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com